ArticleMikrochimica acta2026
Nano-plasmonic SERS-based serum fingerprinting for analytical monitoring of Parkinson's disease and therapeutic response.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reliable and minimally invasive analytical tools for monitoring molecular alterations associated with Parkinson’s disease (PD) remain limited. In this work, a nano-plasmonic sensing platform based on surface-enhanced Raman spectroscopy (SERS) using citrate-reduced silver nano-colloids is developed as a reproducible microanalytical method for serum fingerprinting of PD. The platform enables label-free detection of disease-associated biochemical and conformational changes by enhancing vibrational signatures at the nano-bio interface. Distinct Raman bands at 1138, 1190, and 1740 cm−¹, together with systematic variations in the amide I region, reveal perturbations in protein-, lipid-, and metabolite-associated vibrational signatures, including changes in protein secondary structure and lipid dysregulation. Quantitative deconvolution analysis demonstrates a significant increase in the β-sheet/α-helix ratio with disease severity, providing a conformational spectral metric for monitoring neurodegenerative progression. Multivariate statistical analysis, including principal component analysis and linear discriminant analysis, confirms clear discrimination between diseased and control serum samples, highlighting the platform’s analytical capability to distinguish disease-associated biochemical signatures. Therapeutic intervention with Mucuna pruriens extract produces dose-dependent normalization of SERS spectral fingerprints, consistent with behavioural recovery, attenuation of oxidative stress, and reduced α-synuclein burden. A comparative analysis further indicates that serum yields more consistent and diagnostically robust SERS signatures than brain tissue, owing to lower spatial variability and clearer spectral markers. Overall, the proposed nano-plasmonic SERS strategy establishes a rapid, reproducible, and minimally invasive microanalytical approach for biochemical fingerprinting and therapeutic response monitoring in Parkinson’s disease, demonstrating its potential utility for analytical neurodiagnostics based on serum biomarkers.
Indexed as
Identifiers
41986772What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.